Pain Therapeutics reports abuse-deterrence data for Remoxy ER

Pain Therapeutics Inc. (NASDAQ:PTIE) said Remoxy ER oxycodone extended release (PF-00345439) met the primary endpoint in a Phase I nasal abuse potential study. The company reiterated its plans

Read the full 288 word article

User Sign In